Home > Result Summaries: Compounds > naratriptan > Result Summary for S2WB3002

Result Summary for S2WB3002

Result Summary

Protocol ID:	S2WB3002
Clinical Study ID:	S2WB3002
Official Title:	A randomised, double-blind, placebo-controlled, oral sumatriptan-controlled (100mg), three attack, parallel group study to determine the efficacy, safety and tolerability of oral naratriptan (0.1mg, 0.25mg, 1.0mg and 2.5mg) in the acute treatment of migraine headache.
Phase:	Phase 2
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Bates D, Efficacy and tolerability of naratriptan tablets (0.1 mg-2.5mg) in the acute treatment of migraine: EUR. J. NEUROL. 1998;5 Suppl. 3:S48-S49 Abstract: Efficacy and tolerability of naratriptan tablets (0.1 mg-2.5 mg) in the acute treatment of migraine. Bates, D and Winter, P 3rd Congress of the European Federation of Neurological Societies (EFNS) 9/19/1998 Seville, Spain